Key facts
- This page summarizes Galia Inbar's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 07 Mar 2023, 15:08.
Galia Inbar - 03 Mar 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Reporting relationship
- EVP, Chief Human Resources Officer and Corporate Affairs
- Issuer ticker
- TEVA
- Reported as of
- 03 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Mar 2023, 15:08:25 UTC
- Prior SEC filing
- 02 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov Bergwerk as attorney-in-fact for Galia Inbar
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Galia Inbar filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 07 Mar 2023.
Change
- Previous filing in this sequence was filed on 02 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TEVA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +20,107
- Change %
- +100%
- Price
- Shares after
- 40,301
- Date
- 04 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
TEVA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +5,710
- Change %
- +14%
- Price
- Shares after
- 46,011
- Date
- 05 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TEVA
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +59,760
- Change %
- Price
- $0.000000
- Shares after
- 59,760
- Date
- 03 Mar 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 59,760
- Exercise price
- Footnotes
- F1, F2, F3
TEVA
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -20,107
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 60,321
- Date
- 04 Mar 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 20,107
- Exercise price
- Footnotes
- F1, F2, F4
TEVA
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,710
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 11,422
- Date
- 05 Mar 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 5,710
- Exercise price
- Footnotes
- F1, F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Footnote F3
Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.
Footnote F4
Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025, and March 4, 2026.
Footnote F5
Restricted share units were granted on March 5, 2021, with 5,710 vested on each of March 5, 2022 and March 5, 2023, 5,710 vesting on March 5, 2024, and 5,712 vesting on March 5, 2025.
SEC remarks
EVP, Chief Human Resources Officer and Corporate Affairs